1. Acyclovir resistance in HSV is usually due to a thymidine kinase (TK) mutation, and ganciclovir resistance in CMV is usually due to a UL97 phosphotransferase mutation. Despite arising in different viruses through different enzymes, both forms of resistance leave the same two agents as reliable escape options. What single shared property explains why both foscarnet and cidofovir remain active in both situations?
A) Both are administered orally, bypassing first-pass metabolism
B) Neither agent requires a virus-encoded activating kinase, so loss of viral TK or UL97 does not impair their activity
C) Both are pyrophosphate analogues that chelate the mutant enzymes
D) Both are prodrugs activated by the same host esterase
E) Both inhibit viral entry rather than DNA synthesis
ANSWER: B
Rationale:
The common thread is that neither foscarnet nor cidofovir depends on a virus-encoded activating kinase. Foscarnet acts directly on the viral DNA polymerase pyrophosphate-binding site without any phosphorylation, and cidofovir is activated to its diphosphate by cellular enzymes. Because TK (in HSV) and UL97 (in CMV) are the enzymes lost or altered in the common resistance mechanisms, agents that do not need them retain activity against both ACV-resistant HSV and GCV-resistant CMV, provided the polymerase itself remains susceptible.
Option A: Option A is incorrect: foscarnet and cidofovir are given intravenously, not orally, and route of administration does not explain their retained activity against resistant strains.
Option C: Option C is incorrect: only foscarnet is a pyrophosphate analogue; cidofovir is an acyclic nucleoside phosphonate, and neither works by chelating the mutant enzyme.
Option D: Option D is incorrect: they are not prodrugs sharing a host esterase; the relevant shared feature is independence from viral kinases.
Option E: Option E is incorrect: both agents inhibit viral DNA synthesis at the polymerase, not viral entry.
2. A complete account of acyclovir's action requires integrating its activation sequence with the two ways its active form acts on the viral DNA polymerase. Which option correctly combines both the activation steps and the dual inhibitory mechanism of acyclovir triphosphate?
A) Cellular kinases perform all three phosphorylations, and the drug inhibits the polymerase solely by competing with deoxyguanosine triphosphate (dGTP)
B) Viral thymidine kinase performs all three phosphorylations, and the drug acts only by obligate chain termination
C) Host thymidine kinase performs the first step, and the drug acts by binding the pyrophosphate site of the polymerase
D) Viral thymidine kinase performs the first phosphorylation and cellular kinases complete activation to the triphosphate, which both competes with deoxyguanosine triphosphate (dGTP) and causes obligate chain termination after incorporation
E) No phosphorylation is needed, and the drug acts only by competitive inhibition
ANSWER: D
Rationale:
Acyclovir activation is a two-stage process: virus-encoded thymidine kinase (TK) performs the selectivity-determining first phosphorylation to acyclovir monophosphate, and cellular kinases then complete conversion to acyclovir triphosphate. The triphosphate inhibits the viral DNA polymerase by two mechanisms working together — competitive inhibition relative to deoxyguanosine triphosphate (dGTP) and obligate chain termination after incorporation, because the acyclic sugar lacks the 3'-hydroxyl needed for elongation.
Option A: Option A is incorrect: the first, selectivity-determining phosphorylation is performed by viral TK, not cellular kinases, and the drug acts by both competitive inhibition and chain termination, not competition alone.
Option B: Option B is incorrect: viral TK performs only the first step; cellular kinases complete activation, and the mechanism is dual, not chain termination alone.
Option C: Option C is incorrect: the first step requires viral (not host) TK, and acyclovir does not act at the pyrophosphate site — that is foscarnet's mechanism.
Option E: Option E is incorrect: acyclovir absolutely requires phosphorylation to act, and its mechanism is more than competitive inhibition alone.
3. A learner is asked to connect ganciclovir's molecular selectivity to its clinical toxicity, contrasting it with acyclovir. Which explanation correctly links the selectivity of each drug to the difference in their tolerability?
A) Ganciclovir is concentrated only about 10-fold in CMV-infected cells by UL97, a much narrower selectivity index than acyclovir's roughly 40- to 100-fold gradient in HSV-infected cells, so ganciclovir exposes host cells to more drug and its dose-limiting toxicity is myelosuppression
B) Ganciclovir achieves a larger selectivity gradient than acyclovir, which is why it is better tolerated
C) Both drugs have identical selectivity, so their toxicity differences are unrelated to selectivity
D) Ganciclovir is nonselective because it is activated only by host enzymes, and its main toxicity is nephrotoxicity
E) Acyclovir is less selective than ganciclovir, explaining acyclovir's myelosuppression
ANSWER: A
Rationale:
Ganciclovir's selectivity index is considerably narrower than acyclovir's: the CMV UL97 phosphotransferase concentrates ganciclovir triphosphate only about 10-fold in infected cells, versus acyclovir's roughly 40- to 100-fold gradient in HSV-infected cells. Because more active drug reaches uninfected host cells, ganciclovir is more toxic, and its dose-limiting toxicity is myelosuppression (notably neutropenia), whereas acyclovir's high selectivity makes it exceptionally well tolerated.
Option B: Option B is incorrect: ganciclovir's gradient is smaller, not larger, than acyclovir's; the smaller gradient is why it is more toxic.
Option C: Option C is incorrect: the selectivity indices are not identical, and the toxicity difference is directly tied to selectivity.
Option D: Option D is incorrect: ganciclovir's first activation step is performed by viral UL97 (not host enzymes alone), and its dose-limiting toxicity is myelosuppression, not nephrotoxicity.
Option E: Option E is incorrect: acyclovir is more selective than ganciclovir and does not cause dose-limiting myelosuppression.
4. A hematopoietic stem cell transplant recipient with CMV disease develops severe neutropenia on ganciclovir, and there is concern that the strain may also carry a UL97 mutation. Selecting the next agent requires integrating both the toxicity profile and the resistance spectrum. Which agent best satisfies both considerations, and why?
A) Valganciclovir, because it has a different toxicity profile from ganciclovir and overcomes UL97 mutations
B) Acyclovir, because it spares the marrow and is active against CMV
C) Foscarnet, because it lacks myelosuppression and generally retains activity against UL97-mutant ganciclovir-resistant CMV
D) Cidofovir without probenecid, because it is marrow-sparing and free of toxicity
E) Letermovir, because it treats established CMV disease and reverses neutropenia
ANSWER: C
Rationale:
Foscarnet satisfies both considerations. It does not cause myelosuppression, so it will not worsen the neutropenia, and because it acts directly on the viral DNA polymerase without requiring UL97-mediated activation, it generally retains activity against UL97-mutant ganciclovir-resistant CMV. This combination of a marrow-sparing profile and retained activity against the suspected resistant strain makes it the best fit.
Option A: Option A is incorrect: valganciclovir is simply the oral prodrug of ganciclovir, sharing its myelosuppression and its dependence on UL97, so it addresses neither problem.
Option B: Option B is incorrect: acyclovir has no meaningful activity against CMV because CMV lacks viral thymidine kinase.
Option D: Option D is incorrect: cidofovir is not free of toxicity — it causes dose-dependent nephrotoxicity and requires probenecid plus saline — and omitting probenecid would increase renal harm.
Option E: Option E is incorrect: letermovir is approved for CMV prophylaxis, not treatment of established disease, and does not reverse neutropenia.
5. Brincidofovir was engineered from cidofovir specifically to change how the drug enters cells, and that single design change accounts for two clinically important differences between the two agents. Which option correctly links the entry mechanism to both differences?
A) Brincidofovir uses OAT1 like cidofovir, which is why both are equally nephrotoxic and both are oral
B) Cidofovir enters via lipid pathways, which is why it is oral and non-nephrotoxic
C) Brincidofovir requires viral thymidine kinase for entry, which limits it to HSV and makes it oral
D) Both agents enter only by passive diffusion, so route and toxicity are identical
E) Brincidofovir enters cells via lipid transport pathways instead of OAT1, which both reduces proximal tubular exposure (less nephrotoxicity) and improves oral bioavailability, whereas cidofovir's OAT1 uptake drives its nephrotoxicity and it is given intravenously
ANSWER: E
Rationale:
The defining change is the cellular entry route. Cidofovir is taken into proximal tubular cells by the organic anion transporter 1 (OAT1), which both drives its dose-dependent nephrotoxicity and, together with poor oral absorption, confines it to intravenous use. Brincidofovir, the lipid conjugate, enters cells through lipid transport pathways rather than OAT1; this single change reduces proximal tubular exposure (markedly less nephrotoxicity) and improves oral bioavailability. One mechanistic difference thus explains both the toxicity and the route differences.
Option A: Option A is incorrect: brincidofovir specifically avoids OAT1, so the agents are not equally nephrotoxic, and cidofovir is intravenous, not oral.
Option B: Option B is incorrect: it reverses the agents — cidofovir uses OAT1 and is intravenous and nephrotoxic, not lipid-entering and oral.
Option C: Option C is incorrect: brincidofovir does not require viral thymidine kinase and is not limited to HSV.
Option D: Option D is incorrect: the agents differ precisely because brincidofovir uses lipid transport rather than the OAT1 route, so route and toxicity are not identical.
6. A transplant program reviews why one serostatus group requires the most careful CMV planning. Integrating baseline risk with the behavior of universal prophylaxis, which statement best explains why CMV-seropositive-donor into CMV-seronegative-recipient (D+/R-) patients are doubly vulnerable?
A) They have the lowest baseline risk but uniquely develop early CMV disease during prophylaxis
B) They carry the highest baseline risk of CMV infection and end-organ disease, and they are also the group most prone to late-onset CMV disease after universal prophylaxis is discontinued because immune reconstitution may still be incomplete
C) They are protected by pre-existing immunity, so prophylaxis is unnecessary
D) Their risk derives entirely from the donor being seronegative
E) They are at high baseline risk but never develop late-onset disease
ANSWER: B
Rationale:
D+/R- patients receive latent CMV with the graft while having no pre-existing CMV immunity, giving them the highest baseline risk of infection (50% to 80%) and end-organ disease (20% to 30%) without prophylaxis. They are also the group most prone to late-onset CMV disease after universal prophylaxis ends, because their CMV-specific immune reconstitution may still be incomplete when the drug is stopped. Both features together make them doubly vulnerable.
Option A: Option A is incorrect: D+/R- patients have the highest, not the lowest, baseline risk, and the characteristic problem is late-onset (post-prophylaxis) disease rather than early disease during prophylaxis.
Option C: Option C is incorrect: D+/R- recipients are seronegative and lack pre-existing immunity, so prophylaxis is most important in this group.
Option D: Option D is incorrect: the risk arises from a seropositive donor transmitting virus to a seronegative recipient, not from a seronegative donor.
Option E: Option E is incorrect: this group is in fact the one most likely to develop late-onset disease, not one that never does.
7. A patient with advanced HIV has progressive HSV ulceration unresponsive to adequate intravenous acyclovir, and a thymidine kinase mutation is presumed. A trainee proposes simply increasing the acyclovir dose. Integrating the resistance mechanism with the appropriate response, which statement is correct?
A) Increasing the acyclovir dose will not help because a thymidine kinase mutation prevents activation regardless of dose; foscarnet is the appropriate salvage agent because it acts directly on the polymerase without requiring viral kinase
B) Increasing the acyclovir dose overcomes thymidine kinase mutations by mass action, so no change in agent is needed
C) The strain is pan-resistant, so no antiviral can help
D) Valacyclovir should be substituted because it activates independently of thymidine kinase
E) Ganciclovir is preferred because it does not depend on any viral enzyme
ANSWER: A
Rationale:
A thymidine kinase (TK) mutation prevents the first activating phosphorylation of acyclovir, so the drug cannot be converted to its active form no matter how high the dose — dose escalation is futile. Foscarnet is the appropriate salvage agent because it inhibits the viral DNA polymerase directly and requires no viral kinase, so it remains active against TK-deficient acyclovir-resistant HSV.
Option B: Option B is incorrect: raising the dose does not overcome loss of TK-mediated activation; the activation step itself is blocked.
Option C: Option C is incorrect: the strain is not pan-resistant — it remains susceptible to foscarnet (and cidofovir).
Option D: Option D is incorrect: valacyclovir is merely a prodrug of acyclovir and depends on the same TK activation, so it cannot circumvent the mutation.
Option E: Option E is incorrect: ganciclovir does depend on a viral enzyme (UL97 in CMV) for activation and is not the standard choice for TK-mutant acyclovir-resistant HSV.
8. An immunocompetent adult with herpes zoster could be treated with intravenous acyclovir, but an oral regimen is preferred for outpatient management. Applying what is known about valacyclovir's pharmacokinetics, why can oral valacyclovir serve as an effective substitute in this setting?
A) Because valacyclovir bypasses the need for acyclovir entirely and acts by a separate mechanism
B) Because zoster is more susceptible to acyclovir than HSV, so any oral dose suffices
C) Because valacyclovir is not renally cleared and therefore accumulates to very high levels
D) Because valacyclovir is efficiently absorbed and rapidly converted to acyclovir, achieving plasma acyclovir concentrations several-fold higher than oral acyclovir and approximating intravenous acyclovir exposure, so an oral regimen (e.g., 1 g three times daily) can substitute for the intravenous route in immunocompetent zoster
E) Because valacyclovir is active without conversion to acyclovir
ANSWER: D
Rationale:
Valacyclovir is efficiently absorbed and then rapidly hydrolyzed to acyclovir, producing plasma acyclovir concentrations three to five times higher than equivalent oral acyclovir and approximating those achieved with intravenous acyclovir. This is why an oral valacyclovir regimen (for example, 1 g three times daily) can effectively substitute for intravenous acyclovir in zoster in immunocompetent adults, enabling outpatient therapy.
Option A: Option A is incorrect: valacyclovir works precisely by being converted to acyclovir; it does not act by a separate mechanism.
Option B: Option B is incorrect: VZV is actually less susceptible to acyclovir than HSV, so the rationale is the prodrug's superior exposure, not that any low oral dose suffices.
Option C: Option C is incorrect: acyclovir (from valacyclovir) is renally cleared and requires renal dose adjustment; the advantage is improved absorption, not failure to clear.
Option E: Option E is incorrect: valacyclovir must be converted to acyclovir to be active.
9. A resident is asked to map CMV resistance genotypes to expected drug susceptibility. Integrating the function of each gene with each drug's mechanism, which statement correctly describes the susceptibility consequences of an isolated UL97 mutation versus a UL54 mutation?
A) An isolated UL97 mutation confers resistance to foscarnet while ganciclovir remains fully active
B) A UL54 mutation affects only ganciclovir and never foscarnet or cidofovir
C) An isolated UL97 mutation confers ganciclovir resistance while foscarnet generally remains active, whereas UL54 (polymerase) mutations can confer cross-resistance involving ganciclovir, foscarnet, and cidofovir
D) Both UL97 and UL54 mutations leave all CMV antivirals fully effective
E) An isolated UL97 mutation confers resistance to every CMV antiviral simultaneously
ANSWER: C
Rationale:
UL97 encodes the phosphotransferase that activates ganciclovir, so an isolated UL97 mutation impairs ganciclovir activation and confers ganciclovir resistance, while foscarnet — which acts directly on the polymerase without needing UL97 — generally remains active. UL54 encodes the DNA polymerase itself, so UL54 mutations can confer cross-resistance that involves ganciclovir, foscarnet, and cidofovir depending on the specific mutation. Mapping the gene to the mechanism predicts the susceptibility pattern.
Option A: Option A is incorrect: a UL97 mutation impairs ganciclovir, not foscarnet; foscarnet usually remains active.
Option B: Option B is incorrect: UL54 polymerase mutations can affect foscarnet and cidofovir as well, not ganciclovir alone.
Option D: Option D is incorrect: these mutations do confer resistance — UL97 to ganciclovir and UL54 across multiple agents — so not all drugs remain effective.
Option E: Option E is incorrect: an isolated UL97 mutation does not confer resistance to every CMV antiviral; foscarnet typically still works.
10. A neonate with skin vesicles, seizures, and a maternal history of genital HSV is being managed. Integrating the principles of emergency treatment, the role of confirmatory testing, and the value of subsequent suppression, which sequence of actions is correct?
A) Withhold antivirals until cerebrospinal fluid (CSF) HSV polymerase chain reaction (PCR) returns, then start oral acyclovir
B) Start foscarnet immediately, since neonatal HSV is typically acyclovir-resistant
C) Start ganciclovir, since neonatal central nervous system infection implies CMV
D) Give a single intravenous acyclovir dose, then switch to topical therapy only
E) Begin empiric high-dose intravenous acyclovir immediately without waiting for PCR, send confirmatory testing in parallel, and after completing the intravenous course provide oral acyclovir suppression to improve neurodevelopmental outcomes in CNS or disseminated disease
ANSWER: E
Rationale:
Neonatal HSV is a medical emergency: empiric high-dose intravenous acyclovir (20 mg/kg every 8 hours) is started immediately without waiting for confirmatory testing, while CSF HSV PCR, surface swabs, and liver function tests are sent in parallel. Following the intravenous course, oral acyclovir suppression (300 mg/m2 three times daily for six months) significantly reduces recurrence and improves neurodevelopmental outcomes in infants with central nervous system (CNS) or disseminated disease — integrating acute treatment with secondary suppression.
Option A: Option A is incorrect: therapy must not be delayed for PCR results; empiric intravenous acyclovir is started at once.
Option B: Option B is incorrect: neonatal HSV is not typically acyclovir-resistant; acyclovir is first-line, with foscarnet reserved for documented resistance.
Option C: Option C is incorrect: the pathogen is herpes simplex virus treated with acyclovir, not CMV requiring ganciclovir.
Option D: Option D is incorrect: a single dose followed by topical therapy is inadequate; a full intravenous course and then oral suppression are required.
11. Letermovir is valued in hematopoietic stem cell transplant (HSCT) prophylaxis for two reasons that both flow from its distinct molecular target. Integrating its mechanism with these advantages, which statement is correct?
A) Letermovir targets the viral DNA polymerase, which is why it shares cross-resistance with ganciclovir but spares the marrow
B) Letermovir inhibits the CMV terminase complex (UL56 subunit), a target distinct from the DNA polymerase; this explains both its lack of cross-resistance with ganciclovir, foscarnet, and cidofovir and its absence of myelosuppression, making it especially useful for prophylaxis in HSCT recipients
C) Letermovir is a nucleoside analogue activated by UL97, which is why it overcomes ganciclovir resistance
D) Letermovir causes dose-limiting neutropenia similar to ganciclovir but is preferred for its oral route
E) Letermovir's advantages come from chelating divalent cations, like foscarnet
ANSWER: B
Rationale:
Letermovir inhibits the CMV terminase complex by targeting its UL56 subunit, a mechanism entirely separate from the DNA polymerase inhibitors. Because the target is different, the drug has no cross-resistance with ganciclovir, foscarnet, or cidofovir, and because it does not interfere with the pathways that ganciclovir does, it lacks myelosuppression. Both advantages flow from the same novel target, which is why letermovir is especially useful for CMV prophylaxis in HSCT recipients.
Option A: Option A is incorrect: letermovir does not target the DNA polymerase and does not share cross-resistance with ganciclovir; that is the opposite of its key advantage.
Option C: Option C is incorrect: letermovir is not a UL97-activated nucleoside analogue; it is a terminase inhibitor.
Option D: Option D is incorrect: letermovir notably lacks myelosuppression, unlike ganciclovir.
Option E: Option E is incorrect: letermovir does not work by chelating divalent cations — that property belongs to foscarnet.
12. A pregnant woman develops varicella-zoster virus (VZV) pneumonia, a condition that carries roughly 40% maternal mortality if untreated. Integrating antiviral safety data in pregnancy with the need to treat a life-threatening infection, what is the appropriate approach?
A) Treat with acyclovir (or valacyclovir), which are Pregnancy Category B agents supported by extensive human safety data and indicated for VZV pneumonia in pregnancy, while reserving ganciclovir and foscarnet for life-threatening CMV disease because they are generally avoided in pregnancy
B) Withhold all antivirals because every herpesvirus antiviral is contraindicated in pregnancy
C) Use ganciclovir first-line because it is the safest antiviral in pregnancy
D) Use foscarnet first-line because it has the strongest pregnancy safety record
E) Delay therapy until after delivery regardless of maternal status
ANSWER: A
Rationale:
Acyclovir and valacyclovir are Pregnancy Category B agents supported by extensive human experience, including the Acyclovir in Pregnancy Registry, and they are indicated for serious VZV disease such as VZV pneumonia, which carries about 40% maternal mortality if untreated. Ganciclovir and foscarnet, by contrast, are generally avoided in pregnancy because of teratogenic potential and are reserved for maternal life-threatening CMV disease. Integrating safety with urgency, acyclovir/valacyclovir is the correct choice here.
Option B: Option B is incorrect: acyclovir and valacyclovir are considered safe in pregnancy, so antivirals are not all contraindicated.
Option C: Option C is incorrect: ganciclovir is generally avoided in pregnancy and is not the safest agent.
Option D: Option D is incorrect: foscarnet is also generally avoided in pregnancy and does not have the strongest safety record; acyclovir/valacyclovir carry the favorable data.
Option E: Option E is incorrect: delaying therapy in life-threatening VZV pneumonia would be dangerous given its high untreated maternal mortality.
13. A patient starting foscarnet requires a monitoring and prevention plan that addresses its interrelated toxicities. Integrating foscarnet's renal and electrolyte effects with the appropriate preventive measures, which plan is correct?
A) Monitor complete blood counts twice weekly and give granulocyte colony-stimulating factor, since myelosuppression is the main concern
B) Give probenecid before and after each dose to block OAT1-mediated tubular uptake
C) No monitoring is required because foscarnet is renally inert and electrolyte-neutral
D) Provide mandatory saline prehydration before each infusion to reduce nephrotoxicity, and monitor serum calcium, magnesium, potassium, and phosphate with each dose because foscarnet chelates divalent cations and characteristically causes hypocalcemia, alongside serial serum creatinine
E) Restrict all fluids to concentrate the drug at the site of action
ANSWER: D
Rationale:
Foscarnet's major toxicity is severe nephrotoxicity, mitigated by mandatory saline prehydration (500 to 1000 mL of normal saline) before each infusion. It also chelates divalent cations, characteristically causing hypocalcemia along with hypomagnesemia, hypokalemia, and phosphate disturbances, so serum calcium, magnesium, potassium, and phosphate must be checked with each dose, together with serial serum creatinine. These measures form an integrated plan addressing both the renal and electrolyte effects.
Option A: Option A is incorrect: foscarnet notably lacks myelosuppression, so CBC monitoring and G-CSF are not the central concern; that plan fits ganciclovir.
Option B: Option B is incorrect: probenecid to block OAT1 uptake is the cidofovir protocol, not the foscarnet plan.
Option C: Option C is incorrect: foscarnet is far from renally inert and is a major cause of electrolyte disturbance, so monitoring is essential.
Option E: Option E is incorrect: fluid restriction would worsen nephrotoxicity; vigorous saline prehydration is required.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.